Agilent Technologies (A) stock is back in focus after a packed stretch of news, including expanded FDA approval for its PD-L1 diagnostic, a new artificial intelligence collaboration with OpenAI and Boston Consulting Group, and stronger than expected quarterly results with raised guidance.
See our latest analysis for Agilent Technologies.
The recent AI collaboration and product launches have coincided with a 17.73% 1 month share price return and a 20.25% 3 month share price return. The 1 year total shareholder return of 22.44% points to momentum building over a longer horizon.
If you are watching how AI and digital workflows shape the next wave of lab tools, it may be worth scanning other opportunities through our screener for 61 profitable AI stocks that aren't just burning cash
Agilent now trades at $138.37, with an intrinsic value estimate implying roughly a 20% discount and a 16% gap to the average analyst target. So are you looking at an underappreciated compounder, or a stock already pricing in future growth?
Most Popular Narrative: 14.1% Undervalued
At $138.37, the most followed narrative pegs Agilent Technologies’ fair value at about $161, which points to a meaningful gap for investors to weigh.
Strategic investments in higher-margin recurring revenue streams, including consumables, software, services, and digital platforms, are gaining traction, with CrossLab and services delivering consistent mid-single-digit growth and high customer satisfaction, indicating further margin expansion and greater earnings stability in future periods.
Want to see what sits behind that valuation gap? The narrative leans heavily on compounding revenue, rising margins, and a richer earnings mix over time.
Result: Fair Value of $161.07 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are real pressure points to watch, including tariff related cost headwinds and any prolonged slowdown in government or academic lab funding that could weaken demand.
Find out about the key risks to this Agilent Technologies narrative.
Next Steps
Does this all sound optimistic or cautious to you? Take a moment to review the data points, pressure tests, and valuation gaps yourself, then weigh the 3 key rewards
Looking for more investment ideas?
Do not stop with just one stock. Use powerful screens to spot fresh ideas so you are not looking back later wishing you had started sooner.
- Target potential mispricing by scanning the market for companies flagged in our value focused list through 46 high quality undervalued stocks
- Prioritise financial strength by filtering for opportunities highlighted in the solid balance sheet and fundamentals stocks screener (47 results)
- Unearth earlier stage opportunities by reviewing the 24 elite penny stocks with strong financials
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com